Merck and Roche expand agreement in fight against chronic hepatitis C
20 July 2011 | By Merck
Merck has signed a new non-exclusive agreement with Roche...
List view / Grid view
20 July 2011 | By Merck
Merck has signed a new non-exclusive agreement with Roche...
19 July 2011 | By Roche
Roche has signed an agreement to acquire 100% of mtm laboratories AG (mtm)...
15 July 2011 | By Roche
Roche plans to seek approval with Health Authorities based on encouraging results...
24 June 2011 | By Roche
Roche and Evotec AG announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs...
23 June 2011 | By Roche
Roche announced the launch of a new R&D Institute in France...
20 June 2011 | By Roche
Pivotal Phase II study with vismodegib showed positive results in people with advanced advanced basal cell carcinoma.
5 June 2011 | By Roche
Roche announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...
18 May 2011 | By ThromboGenics NV / BioInvent International AB
Two new studies now ongoing...
17 May 2011 | By Merck
Merck announced that it has entered into agreements with Roche...
11 May 2011 | By Fleming Europe
Network with c-level industry leaders from AstraZeneca, Sanofi Aventis, Roche, Novartis, Baxter, Pfizer & Abbott...
20 April 2011 | By Roche
Roche announced that the FDA has approved the cobas HPV (Human Papillomavirus) Test...
19 April 2011 | By Biogen Idec
Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)...
Lonza (SIX Swiss Exchange: LONN) and Roche (SWX: ROG) announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL® mycoplasma Polymerase Chain Reaction (PCR) assays.
7 April 2011 | By Roche
Roche announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer...
21 March 2011 | By Roche
Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results...